Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Pip Company | Elelgrupi | Sando Pharma | Grasse Pharma Georgia | Medimex |
|---|---|---|---|---|---|
| Total Revenue | 3,003 | 1,699 | 1,341 | — | — |
| Total COGS | -2,936 | -562 | -1,209 | — | — |
| Gross Profit | 67 | 1,136 | 132 | — | — |
| Gross Margin | 2.2% | 66.9% | 9.8% | — | — |
| Total Operating Expenses | -385 | -472 | -439 | — | — |
| EBITDA | -318 | 664 | -307 | — | — |
| EBITDA Margin | -10.6% | 39.1% | -22.9% | — | — |
| Total D&A | -1 | -13 | -43 | — | — |
| EBIT / Operating Income | -319 | 652 | -351 | — | — |
| Total Other Income | -50 | — | 20 | — | — |
| Profit Before Tax | -369 | 652 | -369 | — | — |
| Total Income Tax | -0 | 0 | 0 | — | — |
| Net Profit / (Loss) | -369 | 652 | -369 | — | — |
| Net Margin | -12.3% | 38.4% | -27.5% | — | — |
| Total Interest Expense | — | — | -38 | — | — |
Not every picked company reports every selected year — FY2023: no filing for Medimex and Grasse Pharma Georgia. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2023 | Percentile | Sector n |
|---|---|---|---|---|
| Elelgrupi | Pharma | 39.1% | 89th pct | 123 |
| Pip Company | Pharma | -10.6% | 10th pct | 123 |
| Sando Pharma | Pharma | -22.9% | 7th pct | 123 |
| Grasse Pharma Georgia | Pharma | — | no FY data | 123 |
| Medimex | Pharma | — | no FY data | 123 |
Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.